Letters, Testimony & Comments

July 26, 2001
Honorable Michael Bilirakis Chairman Subcommittee on Health Committee on Energy and Commerce U.S. House of Representatives 2125 Rayburn Building Washington, DC 20015 Dear Mr. Chairman: On June 13, your Subcommittee held a hearing...
July 13, 2001
Dan Eramian, Vice President Communications Biotechnology Industry Organization Athersys Cleveland, Ohio July 13, 2001 Let me start by telling you a little about the Biotechnology Industry Organization, or BIO. We are the national...
July 11, 2001
Written Statement of J. Craig Venter, PhD, President, Celera Genomics On Behalf of The Biotechnology Industry Organization (BIO) Before the Subcommittee on Consumer Protection US House Committee on Energy and Commerce July 11, 2001 Good...
June 20, 2001
Good afternoon. My name is Thomas Okarma. I am the President and CEO of Geron Corporation in Menlo Park, California. Geron is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutic and diagnostic products for...
June 19, 2001
Good afternoon. My name is Thomas Okarma. I am the President and CEO of Geron Corporation in Menlo Park, California. Geron is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutic and diagnostic products...
May 10, 2001
Executive Summary The Biotechnology Industry Organization (BIO) supports amendment of the current reexamination authority to enhance patent quality. Congress established the patent reexamination system in 1980 as an ex parte proceeding that could be...
May 4, 2001
Acting Undersecretary of Commerce and Acting Director of the United States Patent and Trademark Office Regarding Patent Law Harmonization
May 2, 2001
Good afternoon. My name is Carl Feldbaum. I am the president of the Biotechnology Industry Organization, otherwise known as BIO. BIO represents more than 950 biotechnology companies, academic institutions and state biotechnology centers in all 50 U....
April 18, 2001
The Biotechnology Industry Organization (BIO) is pleased to submit comments to the Food and Drug Administration (FDA) on the proposed rule "Availability for Public Disclosure and Submission to FDA for Public Disclosure of Certain Data and...
April 18, 2001
The Biotechnology Industry Organization (BIO) is pleased to submit comments to the Food and Drug Administration (FDA) on the proposed rule "Availability for Public Disclosure and Submission to FDA for Public Disclosure of Certain Data and...
April 11, 2001
By: Lila Feisee BIO's Director for Federal Government Relations and Intellectual Property Consider this: We all know that Alexander Fleming discovered penicillin. Some of us know he did it in 1928. But how many people can tell you who...
March 30, 2001
Summary of Testimony of Thomas Okarma, MD, PhD BIO opposes human reproductive cloning. It is too dangerous technically and raises too many ethical and social questions. The voluntary moratorium on human reproductive cloning should remain in...
February 1, 2001
Dear Mr. President: Recently certain groups have announced plans to clone human beings. The Biotechnology Industry Organization (BIO) opposes these efforts, and we urge you to support continuation of the current voluntary moratorium on these...
February 1, 2001
By Dan Eramian Vice President Communications Biotechnology Industry Organization Delivered at the Global Public Affairs Institute Johnson & Johnson New Brunswick, New Jersey February 1, 2001 Good Morning … thank you for...
January 17, 2001
President-Elect George W. Bush Bush-Cheney Transition Headquarters 1800 G Street, N.W. Washington, DC 20270 Dear President-Elect Bush: The undersigned 123 patient, research, and academic institutions, write to express their strong support...
December 12, 2000
The Biotechnology Industry Organization (BIO) submits these comments on the proposal published by the National Institutes of Health (NIH) in 65 Fed. Reg. 77655 (December 12, 2000), to revise the "NIH Guidelines for Research Involving...
July 13, 2000
WASHINGTON, D.C. (July 13, 2000) -- Executives from two Biotechnology Industry Organization (BIO) member companies testified today at a U.S. House Judiciary subcommittee oversight hearing on gene patents and other genomic inventions. In his...
June 1, 2000
By Carl B. Feldbaum, President Ladies and Gentlemen, I'm Carl Feldbaum, President of the Biotechnology Industry Organization, otherwise known as BIO. I want to welcome you here to Boston, and to BIO 2000, which is by far our largest, and...